Thomas Yeager

TL;DR: The existence of ALT adds some complexity to proposed uses of telomere-related parameters in cancer diagnosis and prognosis, and poses challenges for the design of anticancer therapeutics designed to inhibit telomeres maintenance.

TL;DR: It is reported here that ALT cells contain a novel promyelocytic leukemia (PML) body (ALT-associated PML body, APB), which are large donut-shaped nuclear structures containing PML protein, telomeric DNA, and the telomere binding proteins human telomerre repeat binding factors 1 and 2.

TL;DR: It showed that a substantial proportion of STS, osteosarcomas, and astrocytomas, but not papillary thyroid carcinomas use ALT, and the APB assay for ALT is suitable for paraffin-embedded tumors.

TL;DR: Expression of exogenous hTERT in GM847 (GM847/hTERT) cells resulted in lengthening of the shortest telomeres; this is the first evidence that expression of h TERT in ALT cells can induce telomerase that is active at the telomere.

TL;DR: Elevation of p16 levels occurs at senescence in HUCs, including H UCs transformed by human papillomavirus 16 E7 or E6, whose oncoprotein products lead to functional loss of pRb and p53, respectively, and these data suggest that a component of immortalization may be abrogation, either by pRB inactivation or by p16 inactivation, of a p16-mediated Senescence cell cycle block.